This report describes the first case of failure of dihydroartemisinin piperaquine dhappq for the treatment of p. Piperaquine is a promising antimalarial partner drug used in a fixeddose combination with dihydroartemisinin. The combination of dihydroartemisininpiperaquine dp has been assessed in clinical trials for almost a decade, and shown to be highly efficacious against both plasmodium falciparum and p. Efficacy of artesunateamodiaquine, dihydroartemisininpiperaquine and. A change in the malaria treatment policy for vietnam is in process. Artemetherlumefantrine versus dihydroartemisininpiperaquine for treatment of uncomplicated plasmodium falciparum malaria in children aged less than 15 years in guineabissau an openlabel noninferiority randomised clinical trial johan ursing1,2,3, lars rombo2,4, amabelia rodrigues1, poulerik kofoed1,5. A population pharmacokinetic model of piperaquine in pregnant. Dihydroartemisinin definition of dihydroartemisinin by.
Drug resistant malaria strain strikes southeast asia professor tu youyou is a pharmaceutical chemist who won the nobel prize in physiology or medicine in 2015 for her discovery of the drugs artemisinin and dihydroartemisinin. The aim of this study was to investigate the population pharmacokinetics of piperaquine in pregnant and nonpregnant sudanese women with uncomplicated plasmodium falciparum malaria. A sensitivity analysis in which all losses to followup were classed as failures yielded a difference in cumulative parasitological failure rate between chloroquine and dihydroartemisininpiperaquine of 1. Ibasunate dihydroartemisinin and piperaquine phosphate. In studies of people living in asia, dihydroartemisinin piperaquine is as effective as artesunate plus mefloquine at treating malaria moderate quality evidence. Dihydroartemisinin piperaquine holds promise as an option. A high number of treatment failures 1440 was found, and piperaquine resistance in vietnam was confirmed. The spread of artemisininresistant plasmodium falciparum. Treatment failures in cases with pfpm2 amplificationpositive parasites and adequate piperaquine exposure support the presence of piperaquine resistance in vietnam. Efficacy and safety of dihydroartemisininpiperaquine.
The combination dihydroartemisininpiperaquine is an effective antimalarial that is used widely around the world. Intrasubject variability of piperaquine ranges from 22. It is a semisynthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other. An indonesian observational study detected a higher rate of abortion after first trimester exposure to dihydroartemisininpiperaquine poespoprodjo 2014.
Dihydroartemisinin piperaquine study drugs were provided free of charge by holleypharm, china. Dihydroartemisininpiperaquine for the prevention of malaria. Dihydroartemisininpiperaquine dpq is recommended for. To treat malaria cases, health workers primarily use a combination of dihydroartemisinin and piperaquine, or dhappq.
Researchers tested the efficacy of threedose and monthlydose dihydroartemisininpiperaquine and compared the results with sulfadoxinepyrimethamine. Dihydroartemisininpiperaquine dhappq is a new coformulated and well tolerated act, increasingly used in southeast asia where it has proved to be highly effective against plasmodium falciparum malaria. Artemisininbased combination regimens are recommended by who for the treatment of uncomplicated plasmodium falciparum malaria. Act to combat malaria receives marketing authorization. One such combination comprises the artemisinin derivative dihydroartemisinin and the bisquinolone piperaquine. Embargoed until noon, wednesday 30 november 2011 press release eurartesim dihydroartemisinin piperaquine act to combat malaria receives marketing authorization from ema a fixeddose combination therapy to combat malaria, eurartesim, dihydroartemisinin piperaquine the product of italian research conducted by sigmatau and mmv, approved by the european medicines. The combination dihydroartemisinin piperaquine is an effective antimalarial that is used widely around the world. Eurartesim dihydroartemisininpiperaquine act to combat malaria receives marketing authorization from ema a fixeddose combination therapy to combat malaria, eurartesim, dihydroartemisininpiperaquine the product of italian research conducted by sigmatau and mmv, approved by the european medicines agency ema. Use of the information, documents and data from the echa website is subject to the terms and conditions of this legal notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the echa website may be reproduced, distributed andor used, totally or in part, for noncommercial purposes provided. Efficacy of dihydroartemisininpiperaquine for the treatment of uncomplicated plasmodium falciparum and plasmodium vivax in cambodia, 20082010. Dec 31, 2014 shortterm impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province zambia. The acts adopted differ, with cambodia and indonesia using dihydroartemisininpiperaquine dp and. Dihydroartemisininpiperaquine dhappq is the artemisinin combination therapy that was recently introduced for the treatment of plasmodium falciparum uncomplicated malaria, but emerging resistance in southeast asia is threatening its use.
Plasmodium falciparum dihydroartemisininpiperaquine failures in. The emergence and spread of fit artemisininresistant p falciparum parasite lineages, which then acquire partner drug resistance across the greater mekong subregion. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. In southeast asia, where resistance has emerged towards both artemisinin and piperaquine, the combination is being trialed with a third drug, namely mefloquine. This report describes a case of dhappq treatment failure in uncomplicated malaria occurring in an immigrant living in italy. The dramatic decline in efficacy of dihydroartemisinin piperaquine compared with what was observed in a study at the same location in 2010 was strongly associated with a new triple mutation including the kelch cys580tyr substitution. Current trends in malaria and tuberculosis chemotherapy three of the regimes had excellent and similar efficacy in treating the malaria attack, but of those, treatment with combination dihydroartemisininpiperaquine the combination most recent recommended by the. Dec 22, 2015 the declining efficacy of dihydroartemisinin piperaquine against plasmodium falciparum in cambodia, along with increasing numbers of recrudescent cases, suggests resistance to both artemisinin and piperaquine. Dihydroartemisinin is an active metabolite of the antimalarial drugs artemether item no. The safety and efficacy of a novel combination of dihydroartemisinin dha and piperaquine, artekin holleykin pharmaceuticals, were assessed in 106 patients 76 children and 30 adults with uncomplicated falciparum malaria from 2 remote areas in cambodia. The auc of dihydroartemisinin seems to increase more than proportionally with increasing dose.
Formulation of dihydroartemisininpiperaquine dhp generic tablet as antimalarials drug. Piperaquine phosphate salt used in dosage form sae. Wellcome trust southeast asian tropical medicine research programmes pdf, 177kb. If this is your first visit, be sure to check out the faq by clicking the link above. Davis, sean hewitt, sandra incardona, khim nimol, thierry fandeur, yi poravuth, chiv lim, doung socheat, efficacy and safety of dihydroartemisininpiperaquine artekin in cambodian children and adults with uncomplicated falciparum malaria, clinical infectious diseases, volume 35, issue 12, 15 december 2002, pages. This report describes the first case of failure of dihydroartemisininpiperaquine dhappq for. To start viewing messages, select the forum that you want to visit from the selection below. Leang r, barrette a, mey bouth d, menard d, abdur r, duong s, ringwald p. Studies have shown that eurartesims long halflife affords patients a useful period of protection from new malaria. Listing a study does not mean it has been evaluated by the u. Failure of dihydroartemisininpiperaquine treatment of.
This report describes a case of dhappq treatment failure in uncomplicated malaria occurring in an immigrant living in italy, after a travel to. A change in the malaria treatment policy to treat with artesunate. Dihydroartemisinin piperaquine and artemetherlumefantrine for treating uncomplicated malaria in african children. A fifth combination has recently been added dihydroartemisininpiperaquine 74. Dihydroartemisinin is rapidly cleared from plasma with an elimination halflife of about 12 hours. Artemetherlumefantrine versus dihydroartemisininpiperaquine.
Dihydroartemisininpiperaquine treatment failure in. Piperaquine tetraphosphate is a socalled bisquinolone. Despite the success of act in reducing the global burden of malaria, the emerging of resistance to artemisinin threatens its use. Dihydroartemisininpiperaquine failure associated with a. Dihydroartemisininpiperaquine holds promise as an option for malaria prevention in pregnancy 10. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. The declining efficacy of dihydroartemisininpiperaquine against. Table1, has been used as both mono and combination therapy 6. Available in vitro piperaquine susceptibility assays do not correlate with treatment outcome.
Use of the information, documents and data from the echa website is subject to the terms and conditions of this legal notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the echa website may be reproduced, distributed andor used, totally or in part, for noncommercial purposes provided that echa is. For piperaquine, only in the case of a crossover study, the analytical. Patient information and corresponding data from in vitro piperaquine survival assays performed on 32 cultureadapted p. Data sources include ibm watson micromedex updated 4 may 2020, cerner multum updated 4 may.
Piperaquine is a longacting component of dihydroartemisinin piperaquine, one of the artemisinin combination therapies recommended by the world health organization to treat p. Although dihydroartemisinin piperaquine dp treatment is a welltolerated, effective therapy for uncomplicated malarial infections, this drug combination is known to interfere with cardiac repolarization by prolonging qt intervals on electrocardiograms. The declining efficacy of dihydroartemisininpiperaquine against plasmodium falciparum in cambodia, along with increasing numbers of recrudescent cases, suggests resistance to both artemisinin and piperaquine. Plasmodium falciparum dihydroartemisininpiperaquine failures. Dihydroartemisininpiperaquine, one of the last remaining medications effective against multidrugresistant plasmodium falciparum, was adopted as the firstline antimalarial agent in cambodia in. Efficacy of dihydroartemisinin piperaquine for the treatment of uncomplicated plasmodium falciparum and plasmodium vivax in cambodia, 20082010. The drug was adopted as first line treatment in this country in 2010. It is thought to work by blocking a step in the parasites. Malaria contributes significantly to the global disease burden. Piperaquine is an antimalarial agent first synthesized in the 1960s and used throughout china.
Pdf clinical efficacy of dihydroartemisininpiperaquine for the. For every 5mgkg increase in the dose of piperaquine, the risk of recurrence at day 42 fell by 37%. Dihydroartemisininpiperaquine was associated with a low risk of sudden unexplained death that was not higher than the baseline rate of sudden cardiac death. The funders had no involvement in the study design, data collection, data analysis, data interpretation, in the writing of the paper, or in the decision to submit it for publication. Artemisinin combination therapy act is used worldwide as the firstline treatment against uncomplicated plasmodium falciparum malaria. It is chemically related to other widely available medicines used to treat malaria. Dec 15, 2012 artemisininbased combination regimens are recommended by who for the treatment of uncomplicated plasmodium falciparum malaria. Act to combat malaria receives marketing authorization from ema. Formulation of dihydroartemisininpiperaquine dhp generic tablet as antimalarials drug article pdf available september 2016 with 631 reads how we measure reads. Dihydroartemisininpiperaquine failure in cambodia nejm. Dihydroartemisinin piperaquine and artemetherlumefantrine probably have similar side effects moderate quality evidence. Pdf the efficacy of dihydroartemisininpiperaquine and. Dihydroartemisininpiperaquine is an especially attractive combination therapy, given its prolonged posttreatment prophylactic effect. The funding source had no involvement in the authors work.
Dihydroartemisinin 40 mg and piperaquine phosphate 320 mg capsules. Apr 21, 2010 a sensitivity analysis in which all losses to followup were classed as failures yielded a difference in cumulative parasitological failure rate between chloroquine and dihydroartemisinin piperaquine of 1. Its use declined in the 1980s as piperaquine resistant strains of plasmodium falciparum appeared and artemisinin derivatives became available. Efficacy and safety of dihydroartemisininpiperaquine for treatment. As a result of increasing resistance to sulfadoxinepyrimethamine, new treatments are necessary to prevent malaria in pregnant women in africa. Information on dihydroartemisinin and piperaquine currently available to pqtm indicates that the intrasubject variability of dihydroartemisinin ranges from 21. The marketing authorisation holder shall agree the format and content of the physician leaflet with the.
Mar 10, 2016 dihydroartemisininpiperaquine is an especially attractive combination therapy, given its prolonged posttreatment prophylactic effect. After oral administration of piperaquine tetraphosphate, peak plasma concentrations of piperaquine are observed. A fixed oral combination of the bisquinolone piperaquine and dihydroartemisinin dhp is a new and promising artemisininbased combination therapy. Strict regulation and monitoring of antimalarial use, along. Dihydroartemisininpiperaquine versus chloroquine to treat. Dr jenny hill, liverpool school of tropical medicine, pembroke place, liverpool l37 3qa, uk. Dihydroartemisinin is the active metabolite of all artemisinin compounds artemisinin, artesunate, artemether, etc. Plasmodium falciparum dihydroartemisininpiperaquine. Sep 08, 2006 dihydroartemisinin piperaquine dhappq is a new coformulated and well tolerated act, increasingly used in southeast asia where it has proved to be highly effective against plasmodium falciparum malaria. A fifth combination has recently been added dihydroartemisinin piperaquine 74. Does the use of dihydroartemisininpiperaquine in treating. The efficacy of dihydroartemisininpiperaquine and artemether.
Dihydroartemisinin an overview sciencedirect topics. The world health organization recommended the use of artemisininbased combination therapies acts for treatment of uncomplicated falciparum malaria a decade ago in response to problems of drug resistance. Concerns about repolarisationrelated cardiotoxicity need not limit its current use for the prevention and treatment of malaria. Since 2010, dp has been recommended by who for the treatment of uncomplicated falciparum malaria 5. Pdf artemisininbased combination therapies acts are currently used as the firstline therapy for uncomplicated plasmodium falciparum.
Warning this product is not for human or veterinary use. We tested the efficacy, safety and tolerability of dhappq in patients with uncomplicated p. Monitoring the efficacy of artemisininbased combination therapies is of paramount importance to. Malaria is an infection caused by a parasite known as plasmodium and spread through the bite of an infected mosquito. Bassat q, mulenga m, tinto h, piola p, borrmann s, et al. The effect of dosing regimens on the antimalarial efficacy. Mar 29, 2018 dihydroartemisinin 40 mg and piperaquine phosphate 320 mg capsules. Pdf formulation of dihydroartemisininpiperaquine dhp. The active substances in eurartesim, piperaquine tetraphosphate and artenimol, are antimalarial substances which kill the p. Our results suggest that the dominant artemisininresistant p falciparum c580y lineage probably arose in western cambodia and then spread to thailand and laos, outcompeting other parasites and acquiring piperaquine resistance. Article pdf available september 2016 with 650 reads.
A novel assay using a pharmacologically relevant piperaquine dosetime exposure was designed. Find here online price details of companies selling dihydroartemisinin tablets. Dihydroartemisininpiperaquine tetraphosphate 20mg160mg tablets. Dihydroartemisininpiperaquine study drugs were provided free of charge by holleypharm, china. Our results show that 1 k mutation has become dominant and that piperaquine resistance is present in vietnam. Dec, 2014 the competitive product artequick which the chinese launched against coartem and coarsucam is now confronted by resistance like any other monotherapy. Treatment failure of dihydroartemisininpiperaquine for. Application of dihydroartemisinin plus piperaquine for inclusion in the model list of essential medicines pdf, 285kb.
Support letter from medicines for malaria venture pdf, 317kb. Efficacy of artesunateamodiaquine, dihydroartemisinin. A population pharmacokinetic model of piperaquine in. Dihydroartemisinin also known as dihydroqinghaosu, artenimol or dha is a drug used to treat malaria. Current trends in malaria and tuberculosis chemotherapy three of the regimes had excellent and similar efficacy in treating the malaria attack, but of those, treatment with combination dihydroartemisinin piperaquine the combination most recent recommended by the. Dihydroartemisininpiperaquine for the prevention of. Get info of suppliers, manufacturers, exporters, traders of dihydroartemisinin tablets for buying in india. It is thought that the risk of cardiotoxicity may be. The competitive product artequick which the chinese launched against coartem and coarsucam is now confronted by resistance like any other monotherapy. It has come back into use in combination with the artemisinin derivative db11638 as part of the combination product eurartesim. Dihydroartemisininpiperaquine, one of the last remaining medications effective against multidrugresistant plasmodium falciparum, was adopted.
1486 1310 1208 927 117 1101 806 417 38 211 196 1075 834 924 786 320 258 996 287 562 1157 732 558 98 109 1300 1040 402 181 203 437 1305 95 1205 318 793 67 440 149 778 1064 304 1452 401 1096 247 1384 1330 1391 686